| Literature DB >> 30931956 |
Lina Sabatino1, Pamela Ziccardi1, Carmen Cerchia2, Livio Muccillo1, Luca Piemontese3, Fulvio Loiodice3, Vittorio Colantuoni1, Angelo Lupo4, Antonio Lavecchia5.
Abstract
<span class="Gene">Entities:
Mesh:
Substances:
Year: 2019 PMID: 30931956 PMCID: PMC6443668 DOI: 10.1038/s41598-019-41765-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Structures of compounds 1–7.
|
| ||
|---|---|---|
| compd | X | R |
| ( | (CH2)2 | H |
| ( | (CH2)3 | H |
| ( | (CH2)3 | Cl |
| ( | (CH2)3 | Cl |
| ( | (CH2)4 | H |
| ( | (CH2)2O | Cl |
| ( | (CH2)2O | Cl |
| ( | (CH2)4O | Cl |
| ( | (CH2)5O | Cl |
PPARγ transactivation and cell viability activity of chiral phenoxyacetic acid analogues 1–7.
| Compounds | EC50 (µM) | Efficacy (%) | Proliferation IC50 (µM) | Residual viability (%) |
|---|---|---|---|---|
| ( | 0.64 ± 0.06 | 45 ± 1.3 | 19.7 ± 1.7 | 77 ± 3.1 |
| ( | 0.54 ± 0.1 | 48 ± 2.1 | 12.1 ± 1.2 | 70 ± 2.5 |
| ( | 0.35 ± 0.04 | 65 ± 2.4 | 7.3 ± 0.5 | 47 ± 2.3 |
| ( | 0.4 ± 0.05 | 55 ± 1.2 | 4.8 ± 0.35 | 31 ± 1.3 |
| ( | 0.35 ± 0.07 | 60 ± 1.1 | 10.1 ± 0.4 | 60 ± 0.5 |
| ( | 0.65 ± 0.03 | 65 ± 2.5 | 18.7 ± 0.6 | 76 ± 1.5 |
| ( | 0.75 ± 0.05 | 48 ± 2.7 | 25.1 ± 1.8 | 82 ± 2.3 |
| ( | 0.71 ± 0.02 | 40 ± 2.2 | 8.8 ± 0.7 | 40 ± 2.7 |
| ( | 0.51 ± 0.05 | 62 ± 2.3 | 7.8 ± 0.8 | 35 ± 2.5 |
| RGZ | 0.24 ± 0.07 | 100 ± 0.2 | 9.8 ± 0.4 | 57 ± 3.1 |
Figure 1Cell cycle analysis of HT-29 cells treated with increasing amounts of RGZ, (R,S)-3, (S)-3 or (R,S)-7 and p21waf1/cip1 expression evaluation by Western blotting. (A) Flow cytometric assay carried out on HT-29 cells treated or not with the indicated compounds at different concentrations ranging from 1 to 25 µM for 48 hs. HT-29 cells exposed or not to these compounds were harvested, permeabilized and stained with propidium iodide and analyzed by FACS. Data are means ± SD of two independent experiments. *p ≤ 0.05, **p ≤ 0.01 compared to the control. (B) Proliferating HT-29 cells were treated or not for 48 hs with 10 µM of the indicated compounds. Protein extracts were prepared and assessed for p21waf1/cip1 expression in Western blotting analysis. β-Actin was used for protein load normalization. The bar graphs are the mean ± SD of three independent experiments. **p ≤ 0.01 compared to the control.
Figure 2Effects of RGZ, (R,S)-3, (S)-3 and (R,S)-7 on the expression of different protein markers. Proliferating HT-29 cells were treated for 48 hs with 10 µM of the indicated compounds. Specific antibodies against cyclin D1 (A), c-Myc (B), β-catenin (C) and PPARγ (D) respectively, were used in Western blotting analysis. An anti-β-actin antibody was used as a control for protein loading. The graphs of (A) and (B) represent the means ± SD of three independent experiments. **p ≤ 0.01, ***p ≤ 0.005 compared to the control. The bar graphs of (C,D) are the means ± SD of three independent experiments. *p ≤ 0.05 compared to the control. (E) Top-FLASH luciferase assay performed in HEK-293 cells transiently transfected with the Top-FLASH reporter plasmid and exposed to 20 mM LiCl alone or in combination with 1 µM RGZ, (R,S)-3, (S)-3, (R,S)-7 or the vehicle alone (DMSO) for 24 hs is shown. Luciferase activity is reported as fold induction after normalization to β-galactosidase activity used as control of transfection efficiency. The graph represents the mean ± SD of two independent experiments performed in triplicate. *p ≤ 0.05 compared to LiCl exposure.
Figure 3Effects of RGZ, (R,S)-3, (S)-3 and (R,S)-7 on HT-29 cell apoptosis and caspase-3 activation analysis. (A) HT-29 cells were treated for 48 hs with 10 µM of RGZ, (R,S)-3, (S)-3 and (R,S)-7, respectively, stained by Annexin V-propidium iodide and analyzed by flow cytometry. (B) Early (Ann+/PI−) and late (Ann+/PI+) apoptotic cell populations were evaluated and reported in the graphic representation. The bar graphs are the means ± SD of three independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005 compared to the control. (C) Total protein extracts from proliferating HT-29 cells, treated or not with 10 µM RGZ, (R,S)-3, (S)-3 and (R,S)-7, respectively, for 48 hs were analyzed by Western blotting with an anti-caspase 3 antibody. An anti-β-actin antibody was used as a control for protein loading. Significance is indicated as *p ≤ 0.05 compared to only vehicle.
Figure 4PPARγ-dependent antiproliferative effect in CRC-derived RKO cells. Western blotting analysis of p21waf1/cip1 expression in total protein extracts from CRC-derived RKO cells (A) and its derived clone overexpressing an ectopic PPARγ1 (B) using an anti-p21waf1/cip1 antibody. An anti-β-actin antibody was used as a control for protein loading. The bar graphs represent the mean ± SD of PPARγ/β-actin of at least 3 independent experiments. *p ≤ 0.05, **p ≤ 0.01 compared to the control.
Figure 5Docking of compound (S)-3 into the PPARγ binding pocket. (A) Binding mode of representative compound (S)-3 (a partial agonist, yellow sticks) into the PPARγ LBD represented as a limegreen ribbon model. Only amino acids located within 4 Å of the bound ligand are displayed and labeled. H-bonds discussed in the text are depicted as dashed deep-purple lines. (B) 2D ligand-interaction diagram of (S)-3 into the PPARγ LBD generated by the MOE software package. Green spheres = “greasy” residues; spheres with red outline = acidic residues; spheres with blue outline = basic residues; spheres with black outline = polar residues; blue background spheres = receptor exposure to solvent; blue spheres on ligand atoms = ligand exposure to solvent. Green dotted lines = side chain donors/acceptors; blue dotted lines = halogen contact; grey dotted line = proximity contour.